BMY

58.8200.82%
CS

Christopher S. Boerner

CEO & Chairman

Dr. Christopher S. Boerner, also known as Chris, Ph.D., is Independent Director of Colgate-Palmolive Company from March 15, 2026. Dr. Boerner served as Chief Operating Officer at Bristol-Myers Squibb Company since April 26, 2023 to 2023 and served as its Executive Vice President since April 2023 to 2023 and serves as its Director since 2023 and serves as its Chief Executive Officer since November 01, 2023. He is Chairman of Bristol-Myers Squibb Company since April 01, 2024. He joined Bristol-Myers Squibb Company in 2015. He served as Executive Vice President and Chief Commercialization Officer at Bristol-Myers Squibb Company since August 28, 2018 until April 26, 2023. He was President and Head of U.S. Commercial at Bristol-Myers Squibb Company from 2015 to 2017. He was President and Head of International Markets at Bristol-Myers Squibb Company from 2017 until August 28, 2018. He served as the President and Head of the US Commercial business at Bristol-Myers Squibb (BMS). He served as an Executive Vice President of Commercial at Seattle Genetics Inc. since February 2014. He served as Senior Vice President of Commercial at Seattle Genetics Inc. from March 2012 to February 2014 and was its Executive Vice President from 2014 to 2015. He joined BMS in February 2015. He served as a Vice President of Marketing at Seattle Genetics Inc. from December 2010 to March 2012. Prior to Seattle Genetics, he was with Dendreon Corporation from June 2010 to November 2010, where he led the marketing team. He served as a Vice President of Marketing at Dendreon. From 2002 to 2010, he was with Genentech, a Member of the Roche Group, where he served in a variety of commercial roles, including Director of Marketing on Avastin, Director of Avastin franchise management and Associate Director of Oncology Market Development. Prior to Genentech, he was with McKinsey & Company, a global strategic management consulting firm, where he worked on a variety of pharmaceutical sales and marketing engagements. He was a Director of Capital Health System, Inc. since June 17, 2016. He served as a Director of Achaogen, Inc. from April 2, 2014 to June 11, 2015. He holds a Ph.D. and M.A. in Business Administration from the Haas School of Business at the University of California, Berkeley and holds an A.B. in Economics and History from Washington University in St. Louis.

Positions